Pharmaceutical Consulting 2026: What Pays for the Work

The 2026 price rule that changed the client's question

On 1 January 2026 ten drugs covered under Medicare Part D began selling at a government negotiated price. CMS states the point plainly: the list contains the negotiated prices, "which the statute refers to as Maximum Fair Prices (MFPs), for 10 drugs covered under Medicare Part D that will go into effect beginning January 1, 2026".

The ten are Eliquis, Enbrel, Entresto, Farxiga, Imbruvica, Januvia, Jardiance, NovoLog and Fiasp, Stelara, and Xarelto. A second cycle covers fifteen more products with prices applicable in 2027, including Ozempic with Rybelsus and Wegovy, Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Otezla, Calquence, Austedo, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet, Linzess and Ofev.

CMS also publishes the size of the effect in two numbers that can be combined. Had the negotiated prices applied during 2023, they "would have saved an estimated $6 billion in net covered prescription drug costs, which would have represented 22% lower net spending in aggregate". Divide to recover the base: 6 divided by 0.22 gives 27.3, so roughly $27 billion of 2023 net spending across those ten products. Multiply back as a check: 27.3 times 0.22 is 6.0.

That single division explains the consulting demand better than any market forecast. Roughly $27 billion of annual net revenue across ten products is now priced by negotiation instead of by the manufacturer, and CMS separately projects a $1.5 billion saving for Part D enrollees in 2026. Every affected company needs its gross to net model, its channel strategy and its launch pricing rebuilt, and that rebuild is a consulting engagement.

Five products leaving the negotiation list, with dates

The program also removes products, and CMS publishes each removal with its determination month and its effective date. The mechanism is competition: a selected drug stops being selected once an approved generic or a licensed biosimilar referencing it is actually marketed.

Three of the original ten leave the list on the same date, twelve months after they entered it. Read that as a scheduling fact about the work: a market access team that spent 2025 preparing for a negotiated price on Stelara spends 2027 preparing for generic competition on it instead. Those are two different projects with two different analytical cores.

The Xeljanz determination is the one to watch, because its removal date sits in 2029 while the determination was made in June 2026. A candidate who reads the table can see that regulatory timelines in this sector run years ahead of the fiscal year a client is budgeting.

Approval throughput, counted rather than asserted

The upstream clock is the approval rate, and FDA publishes it as a numbered table per year. We counted the rows on 30 September 2026 rather than quoting a figure from a summary.

Calendar 2025 closed with 46 novel drug approvals, numbered 1 to 46, running from Datroway on 17 January 2025 to Nereus on 30 December 2025. The 2026 table held 45 rows through 28 September 2026, with Emcitate the most recent entry.

Forty-five approvals in nine months against forty-six in twelve is a throughput increase of real size, and it matters to anyone choosing this sector. Each novel approval creates a launch, and a launch creates the densest cluster of consulting work in the lifecycle: pricing, payer negotiation, field force sizing, patient support design, and supply readiness.

The two clocks point in opposite directions, and both are published. More products are arriving while the price of established products is being negotiated down. A sector under both pressures buys advice, which is the honest economic reason pharma practices are hiring.

What an exclusivity loss looks like on a real filing

Loss of exclusivity is the sector's defining cliff, and a public filing lets you model one without a single assumption. Merck's 10-K, filed 24 February 2026, states that "Januvia and Janumet will lose market exclusivity in the U.S. in May 2026 and Janumet XR will lose market exclusivity in the U.S. in July 2026". It goes further: following that loss, "the Company anticipates it will lose nearly all U.S. sales of Januvia and Janumet".

The same filing publishes the sales at risk. In 2025 Januvia sold $999 million in the United States and $605 million internationally. Janumet sold $268 million in the United States and $672 million internationally. So the US revenue the company expects to lose is 999 plus 268, which is $1,267 million.

Put that against the company's scale. Total 2025 sales were $65,011 million, so 1,267 divided by 65,011 is 0.0195, which is about 2.0 percent of company revenue disappearing inside a year. The worldwide combined figure checks out against the filing's own line: 1,604 plus 940 is $2,544 million, exactly the "Januvia/Janumet $ 2,544" the filing prints.

Now the number that reframes the whole exercise. The same 10-K states that "in the aggregate, in 2025, sales of Keytruda represented 49% of the Company's total sales", and reports Keytruda at $31,641 million. Check the share: 31,641 divided by 65,011 is 0.487, so 48.7 percent, which rounds to the 49 percent the filing states. The filing then says it "expects that sales of Keytruda will be materially negatively impacted by biosimilar competition between 2028 and 2029".

That is the actual client question. A two percent erosion is a workstream. A concentration of 49 percent facing biosimilars in two years is a company strategy, and it is the kind of problem that keeps four firms on retainer.

Seven firms and the pharmaceutical consulting practice each publishes

Every row below was read on the firm's own domain on 30 September 2026. The second column is the label the firm uses, which varies more than the work does.

The labels disagree about where the boundary sits. Bain files Pharmaceuticals under healthcare, BCG files Biopharma under health care, ZS merges pharma and biotech into one label, PA Consulting puts pharma under life sciences, and IQVIA files its consulting under R&D. McKinsey runs Healthcare and Life Sciences as two practices, which our healthcare consulting firms page documents across thirteen firms.

Only one of the seven publishes a practice headcount. Bain's counters read 1,000+ engagements, 200+ dedicated industry experts, and 85 percent of the top 20 pharma firms served in five years. Nobody else gives a number of that kind, which is why this page cannot rank the practices by size.

Where pharmaceutical consulting work sits in the lifecycle

Read the third column of the table above as one combined list and the sector's work divides into five clusters. The firms use different words for the same five.

1. Research portfolio and asset choices. IQVIA calls it integrated asset development and protocol design optimization. BCG calls it R&D. The analytical core is a probability weighted value across development stages that can fail.
2. Regulatory strategy. PA Consulting names regulatory operations and submissions. IQVIA names regulatory strategy consulting. The deliverable is a filing plan with dates a commercial plan can depend on.
3. Launch and market access. This is where the negotiated price arithmetic above lands, and it is the cluster that grew most in 2026. The question is who reimburses at what price, and what volume follows.
4. Commercial performance on marketed products. ZS names marketing, sales and oncology, and sells a platform alongside the advice. The work is field force sizing, targeting, and channel mix.
5. Manufacturing, supply and cost. PA Consulting delivers this with an engineering partner. Bain names supply chain reinvention. This cluster is the least visible from outside and a large share of the billable work.

An applicant should pick the cluster before picking the firm, because the daily work differs more across clusters than it does across firms inside one cluster. A market access project and a manufacturing network redesign share an industry and nothing else.

What no source publishes about pharmaceutical consulting

Fees first. No firm publishes what an engagement costs, no client discloses it, and no public filing carries it. Any number you see for a pharma consulting day rate is unsourced.

Practice size next. Bain's 200+ is the only figure, and even that counts dedicated experts rather than everyone staffed on pharma work. The others publish none, so a ranking by practice headcount cannot be built from primary sources.

Third, the share of a firm's revenue that comes from pharma. Not published, including by the firms that publish their total revenue. Our McKinsey competitors page sets out which firms publish a revenue line at all.

Fourth, unit prices under the negotiation program. CMS publishes the maximum fair price per product in linked PDF and ZIP files, and we did not open them, so this page quotes no per drug price.

Fifth, the recruiting calendar. None of the seven careers routes publishes a pharma specific deadline or interview date. Your school career office holds the campus window and the firm's recruiter holds the off cycle dates.

One practitioner on pharmaceutical consulting, and what it is worth

First hand accounts of this work are scarce, and the ones that exist are published by employers. ZS runs a careers feature in which Yashasavi Jaipuriyar, a senior manager, describes leading data and technology transformation programs for life sciences clients across data engineering, master data management, analytics and AI solutions.

His description of the job is more specific than any practice page: "What I enjoy most is being able to move between the strategic and the practical. Shaping how we solve a client problem, building the right team around it and then seeing the solution create tangible impact." On what changed as he took bigger teams, he says he wanted "to become better at influencing without always having formal authority".

PA Consulting publishes named practitioners on its practice page, and two of them describe what they see in 2026. One says that "Consumerized therapeutics require a hybrid commercial model: the innovation engine of a new product launch combined with the retail, volume-driven mechanics of a consumer brand." Another argues that AI maturity in clinical development "is not defined by the sophistication of a single model, but by the ability to operationalize AI across the enterprise".

Take all three with the same caveat. These are employer published statements, first hand about what those people do and interested in what they sell. They are useful evidence of the vocabulary a pharma interviewer will use, and weak evidence about the sector as a whole.

How to take a pharma case without sector trivia

Sector knowledge earns fewer points here than candidates expect. An interviewer will hand you any industry fact you need, including reimbursement mechanics. What the sector changes is which structure the prompt deserves, and that has an order.

1. Name the payer before the product. Reimbursement decides volume more reliably than clinical merit does, and after 1 January 2026 the payer may be setting the price directly.
2. Put the regulatory date on the timeline first. An approval window or an exclusivity date bounds every revenue line you are about to build.
3. Weight the pipeline by probability. A phase two asset is not a forecast, and treating it as one is the most common sector error.
4. Check concentration before you model growth. A company earning 49 percent of sales from one product has a different risk profile than one earning 5 percent from each of twenty.
5. Say what happens at loss of exclusivity. A recommendation that stops before the cliff has answered a shorter question than the one asked.

Our drills grade one structure, one calculation or one synthesis at a time and return a scorecard in seconds. The weights are on our method page and they are ours: a market sizing answer scores Assumption chain 30, Scope 25, Arithmetic 25, Sanity check 20. We wrote that rubric. None of the seven firms above publishes one.

Two limits, stated plainly. The tool teaches no industry content, so it will not explain how a formulary works. And our assessment simulators are not running: the /assessments page says 0 of 6 simulators are live, in those words, on the page. What exists today is the drills and the graded scorecard, open without an account. If you want the sector step after this page, our ZS case interview guide and IQVIA case interview guide cover two of the seven firms above in their own process detail.